Please assess the completion status of the following clinical trial:

Trial Title: P. Knowlesi Trial of Artemether-lumefantrine vs Chloroquine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients at least 1 year of age and weighing more than 10kg.~* Microscopic diagnosis P. knowlesi (including diagnosis as P. malariae) or P. falciparum infection (any parasitaemia).~* Negative P. falciparum malaria rapid diagnostic test (histidine rich protein 2)~* Fever (temperature ≥37.5°C) or history of fever in the last 48 hours.~* Able to participate in the trial and comply with the clinical trial protocol.~* Written informed consent to participate in trial; thumbprint is required for illiterate patients, and written consent from parents/guardian for children below age of consent.~Exclusion Criteria:~* Clinical or laboratory criteria for severe malaria, including warning signs, requiring parenteral treatment according to modified WHO criteria (see Appendix 4)~* Parasitaemia \> 20,000 /μL~* Inability to tolerate oral treatment~* Concomitant infection with any other malaria species~* Positive for P. falciparum histidine-rich-protein-2 by malaria rapid diagnostic test~* Pregnancy or lactation~* Unable or unwilling to use contraception during study period~* Known hypersensitivity or allergy to artemisinin derivatives~* Serious underlying disease (cardiac, renal or hepatic)~* Received anti-malarials in previous 2 months~* Previous psychiatric illness or epilepsy~* Previous episode of cerebral malaria

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Artemether-lumefantrine (Type: ACTIVE_COMPARATOR): Artemether-lumefantrine.~1 tablet = 20mg arthemether and 120mg lumefantrine. Dosing at 0, 8, 24, 36, 48 and 60 hours. Dose according to bodyweight; \>35kg = 2 tablets, 26-35kg = 3 tablets, 16-25kg = 2 tablets, \>10-15kg = 1 tablet.
- Chloroquine (Type: ACTIVE_COMPARATOR): Chloroquine.~1 tablet contains 155mg chloroquine base. Adult dose (\>35kg); 620mg (4 tablets) at 0 hours, and 310mg (2 tablets) at 6-8, 24 and 48 hours.~Child dose (\>10-35kg); 10mg/kg at 0 hours, and 5mg/kg at 6-8, 24 and 48 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).